WHO Pharmaceuticals Newsletter 2005, No. 01
(2005; 12 pages) View the PDF document
Table of Contents
Close this folderREGULATORY MATTERS
View the documentAMIODARONE - Medication Guide to be dispensed along with medicine
View the documentATOMOXETINE - Labelling to include liver injury warning
View the documentBENZATHINE BENZYL-PENICILLIN/PROCAINEBENZYLPENICILLIN - Label changes highlight appropriate use
View the documentMEFLOQUINE - Patient Information Leaflet to help recognize adverse symptoms
View the documentPARACETAMOL-DEXTROPROP-OXYPHENE - To be withdrawn due to risk of toxicity in overdose
View the documentSMALLPOX VACCINE - Label to highlight reports of myopericarditis
View the documentTHIORIDAZINE - Withdrawn due to poor benefit/risk profile
Open this folder and view contentsSAFETY OF MEDICINES
Open this folder and view contentsDRUGS OF CURRENT INTEREST
Open this folder and view contentsFEATURE
 

BENZATHINE BENZYL-PENICILLIN/PROCAINEBENZYLPENICILLIN - Label changes highlight appropriate use

USA. King Pharmaceuticals Inc., has issued a 'Dear Health-care Professional' letter advising of changes to the US labelling of benzathine benzylpenicillin/procaine benzylpenicillin (Bicillin C-R) and benzathine benzylpenicillin (Bicillin L-A) that highlight appropriate use and administration of these products. The letter advises that benzathine benzylpenicillin (Bicillin L-A) is the only approved benzylpenicillin indicated for the treatment of venereal disorders, including syphilis, in the USA. However, King Pharmaceuticals has been made aware of post-marketing reports of benzathine benzylpenicillin/procaine benzylpenicillin (Bicillin C-R) being used to treat patients with syphilis; they warn that use of Bicillin C-R instead of Bicillin L-A may result in inadequate treatment. To reflect this important difference, the cartons and syringe labels of the two agents have been modified. In addition, a boxed warning has been added to the labelling of both Bicillin C-R and Bicillin L-A to emphasize that these products are not intended for IV use, which has been associated with heart arrest and death.

Reference:

'Dear Health-care Professional' letter from King Pharmaceuticals Inc., November 2004. Available on the Internet at www.fda.gov

to previous section
to next section
 
 
The WHO Essential Medicines and Health Products Information Portal was designed and is maintained by Human Info NGO. Last updated: October 29, 2018